 | This article is an
orphan, as no other articles
link to it. Please
introduce links to this page from
related articles; try the
Find link tool for suggestions. (July 2024) |
 | |
| Clinical data | |
|---|---|
| Trade names | Aidixi |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
Disitamab vedotin (trade name Aidixi) is a drug for the treatment of various types of solid tumors. [1] It is an antibody-drug conjugate that consists of an immunoglobulin G1 antibody that is linked to the antitumor agent vedotin (monomethyl auristatin E).
Background
In China, disitamab vedotin was approved in 2021 for the treatment of patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two systemic chemotherapy regimens. [2] In the United States, the FDA has granted disitamab vedotin a breakthrough therapy designation for the treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma following treatment with platinum-based chemotherapy. [3]
References
- ^ Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M (December 2022). "Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy". Drug Delivery. 29 (1): 1335–1344. doi: 10.1080/10717544.2022.2069883. PMC 9090390. PMID 35506447.
- ^ Deeks ED (November 2021). "Disitamab Vedotin: First Approval". Drugs. 81 (16): 1929–1935. doi: 10.1007/s40265-021-01614-x. PMID 34661865.
- ^ "Disitamab vedotin plus toripalimab shows promise for advanced urothelial carcinoma". Urology Times. June 8, 2023.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
| This article is an
orphan, as no other articles
link to it. Please
introduce links to this page from
related articles; try the
Find link tool for suggestions. (July 2024) |
|
| |
| Clinical data | |
|---|---|
| Trade names | Aidixi |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
Disitamab vedotin (trade name Aidixi) is a drug for the treatment of various types of solid tumors. [1] It is an antibody-drug conjugate that consists of an immunoglobulin G1 antibody that is linked to the antitumor agent vedotin (monomethyl auristatin E).
Background
In China, disitamab vedotin was approved in 2021 for the treatment of patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two systemic chemotherapy regimens. [2] In the United States, the FDA has granted disitamab vedotin a breakthrough therapy designation for the treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma following treatment with platinum-based chemotherapy. [3]
References
- ^ Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M (December 2022). "Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy". Drug Delivery. 29 (1): 1335–1344. doi: 10.1080/10717544.2022.2069883. PMC 9090390. PMID 35506447.
- ^ Deeks ED (November 2021). "Disitamab Vedotin: First Approval". Drugs. 81 (16): 1929–1935. doi: 10.1007/s40265-021-01614-x. PMID 34661865.
- ^ "Disitamab vedotin plus toripalimab shows promise for advanced urothelial carcinoma". Urology Times. June 8, 2023.
|
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |